INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
复制标题
多发性骨髓瘤的强化治疗和完全缓解的标准
DOI：
10.1016/s0140-6736(89)91548-1
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
T. Mcelwain
中科院分区：
文献类型：
--
作者：
M. Gore;M. Gore;C. Viner;C. Viner;M. Meldrum;M. Meldrum;J. Bell;J. Bell;S. Milan;S. Milan;A. Zuiable;A. Zuiable;M. Slevin;M. Slevin;P. Selby;P. Selby;P. Clark;P. Clark;B. Millar;B. Millar;J. Maitland;J. Maitland;I. Judson;I. Judson;C. Tillyer;C. Tillyer;J. Malpas;J. Malpas;T. Mcelwain;T. Mcelwain
50例既往未接受过治疗的多发性骨髓瘤患者接受了两阶段治疗：长春新碱、多柔比星和甲基强的松龙（VAMP）重复4天输注周期，随后接受高剂量美法仑（HDM），并在可能的情况下进行自体骨髓移植。总有效率为74%（37/50），其中25例患者（50%）达到完全血液学和生化缓解。这些缓解与良好的生活质量相关，这些生活质量通过体力状态、疼痛分级和体液免疫抑制的逆转来衡量。6例患者在VAMP阶段死亡，1例死亡与HDM相关。在如此高比例的患者中实现完全缓解（如本文所定义）是令人期待的，可能代表骨髓瘤管理的有益进展。
50 previously untreated patients with multiple myeloma received two-phase treatment: repeated cycles of 4 day infusion with vincristine, doxorubicin, and methylprednisolone (VAMP) followed by high-dose melphalan (HDM), with autologous bone marrow transplantation where possible. The overall response rate was 74% (37/50), with 25 patients (50%) achieving complete haematological and biochemical remission. These remissions were associated with a good quality of life as measured by performance status, pain grade, and the reversal of humoral immunosuppression. 6 patients died during the VAMP phase and there was 1 death related to HDM. The achievement of complete remission, as defined here, in such a high proportion of patients is exeptional and may represent a useful advance in the management of myeloma.
先前未经治疗的多发性骨髓瘤患者的化疗：近期治疗结果的分析。
影响因子：
4
作者：
Sporn,JR;McIntyre,OR
通讯作者：
McIntyre,OR